Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Equity

v3.24.1.1.u2
Consolidated Statements of Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Treasury Stock
Retained Earnings
Accumulated Other Comprehensive Income (Loss)
Directors
Common Stock
Employees
Common Stock
Executive Officers
Common Stock
Balance, beginning of period (in shares) at Mar. 31, 2021   33,225,808              
Balance, beginning of period at Mar. 31, 2021 $ 378,872 $ 33 $ 231,322 $ 0 $ 183,436 $ (35,919)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of common stock in exercise of stock options (in shares)   8,100              
Issuance of common stock in exercise of stock options 97   97            
Issuance of restricted stock as deferred compensation to directors, employees and executive officers (in shares)             32,136 36,126 62,552
Stock compensation expense 3,803   3,803            
Repurchase of employee stock units on vesting (673)   (673)            
Net income 20,092       20,092        
Foreign currency translation adjustment (2,922)         (2,922)      
Other (65)         (65)      
Balance, end of period (in shares) at Mar. 31, 2022   33,364,722              
Balance, end of period at Mar. 31, 2022 399,204 $ 33 234,549 0 203,528 (38,906)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of restricted stock as deferred compensation to directors, employees and executive officers (in shares)             38,137 40,923 64,294
Stock compensation expense 5,954   5,954            
Repurchase of employee stock units on vesting (643)   (643)            
Net income 33,666       33,666        
Foreign currency translation adjustment (19,202)         (19,202)      
Other $ 9       1 8      
Balance, end of period (in shares) at Mar. 31, 2023 33,508,076 33,508,076              
Balance, end of period at Mar. 31, 2023 $ 418,988 $ 33 239,860 0 237,195 (58,100)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of restricted stock as deferred compensation to directors, employees and executive officers (in shares)             22,829 98,177 101,161
Stock compensation expense 5,754   5,754            
Repurchase of employee stock units on vesting $ (2,058)   (2,058)            
Repurchase of shares under authorized program (in shares) (8,018) (8,018)              
Repurchase of shares under authorized program $ (250)     (250)          
Net income 51,588       51,588        
Foreign currency translation adjustment 836         836      
Other $ 29 $ 1 (1)     29      
Balance, end of period (in shares) at Mar. 31, 2024 33,722,225 33,722,225              
Balance, end of period at Mar. 31, 2024 $ 474,887 $ 34 $ 243,555 $ (250) $ 288,783 $ (57,235)